US$ 22.47
glp 1 and liver function Therapeutic Mechanisms Clinical Effects of Glucagon-like Peptide Receptor Agonists in Nonalcoholic Fatty Disease Current status of glucagon-like peptide-1
Description
Clinical evidence remains limited
There can be side effects and risks: GLP-1 drugs affect multiple systems (pancreas, kidney, GI tract) and are not without cost or health implications

Emerging research has revealed a complex bidirectional interaction between the gut microbiome and cannabis

Metseras pipeline includes MET-097i, a GLP-1 receptor agonist designed for once-monthly dosing, and MET-233i, an amylin analog being developed for monthly administration
